HCPCS Level IIdrugActive
J0896
Inj luspatercept-aamt 0.25mg
BETOS: O1E
Effective: 2020-07-01
Description
Injection, luspatercept-aamt, 0.25 mg
Medicare Part B Drug Pricing
Average Sales Price (ASP) data for Q1 2026
Drug Name
Reblozyl
Manufacturer
Celgene Corporation
HCPCS Dosage
0.25 MG
Billing Units
100.0000
2
NDC Products
asp
Pricing Source
Medicare Part B drugs are reimbursed at ASP + 6%. Pricing updates quarterly based on manufacturer-reported data.